© 2019 Helomics Corp. All rights reserved.

  • White Twitter Icon
  • Facebook - White Circle
  • White LinkedIn Icon

CEO Gerald Vardzel to Present at 9th Annual Biotech Showcase on January 9, 2017

January 5, 2017


PITTSBURGH – January 05, 2017 - Helomics® Corporation, a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotech industries, today announced that CEO Gerald Vardzel will present at the 9th Annual Biotech Showcase™ on Monday, January 9, 2017 at 10:45 a.m. Pacific Time. The conference will take place at the Hilton San Francisco Union Square, San Francisco, CA.


Mr. Vardzel will discuss the new strategic focus of the Helomics laboratories and the company’s product enhancement capabilities including ex-vivo, live-cell tumor growth and how these platforms can be utilized by industry clients to fulfill specific and unique research and developmental needs. Mr. Vardzel will be available for one-on-one meetings at the showcase on Jan. 9th and 10th. For more information or to schedule a meeting, please contact Steven Seegers at sseegers@helomics.com.


About Helomics® Corporation

Helomics® is an integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace.  Helomics offers scientific and non-scientific product enhancement services and advanced clinical laboratory diagnostic tests to provide a customized solution to our client’s specific product development needs.

Helomics® is headquartered in Pittsburgh, Pennsylvania where the company maintains a state-of-the-art research laboratory and a CLIA-certified clinical laboratory. For more information please visit: www.helomics.com.


Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:  This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes”, “expects”, “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.  


For more information, please contact:

Michelle Murgia, Marketing Communications and Design, Helomics Corp.





Source: Helomics® Corporation

Share on Facebook
Share on Twitter
Please reload

Featured Posts

Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis

September 10, 2019

Please reload

Recent Posts
Please reload